Nanovesicles derived from faecalibacterium prausnitzii, and uses thereof

A technology of Faecalibacterium Przewalskii and vesicles, which is applied to nanovesicles derived from Faecalibacterium Przetii and its application field, can solve the problem of unreported Faecalibacterium Przewalski releasing vesicles, and never reported Faecalibacterium Przewalski's cancer. or refractory disease diagnosis and treatment

Pending Publication Date: 2020-08-25
MD HEALTHCARE INC
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the fact that F. prausnitzii releases vesicles extracellularly has not been reported so far, especially the use of F. prausnitzii for the diagnosis and treatment of cancer or refractory diseases such as heart and brain diseases has not been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanovesicles derived from faecalibacterium prausnitzii, and uses thereof
  • Nanovesicles derived from faecalibacterium prausnitzii, and uses thereof
  • Nanovesicles derived from faecalibacterium prausnitzii, and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] Example 1. Analysis of In vivo Absorption, Distribution and Excretion Patterns of Gut Bacteria and Bacteria-Derived Vesicles

[0076] To assess whether gut bacteria and bacterial-derived vesicles are absorbed systemically through the gastrointestinal tract, the following experiments were performed. First, a dose of 50 μg each of fluorescently labeled intestinal bacteria and vesicles derived from intestinal bacteria was administered to the stomach of the mouse through the gastrointestinal tract of the mouse, and the Fluorescence was measured after 1 hour, 6 hours and 12 hours. As a result of observing the whole image of the mouse, as Figure 1A As shown, the bacteria were not taken up systemically, but vesicles derived from the bacteria were absorbed systemically at 5 minutes after administration, and strong fluorescence was observed in the bladder at 3 hours after administration, making it possible to see that the vesicles were excreted into urinary tract. Furthermore...

Embodiment 2

[0078] Example 2. Metagenomic Analysis of Bacteria-Derived Vesicles in Clinical Samples

[0079] After first placing clinical samples (e.g. feces, blood, urine, etc.) middle. After removing bacteria and impurities using a 0.22-μm filter, transfer them to a Centriprep tube (centrifugal filter 50kD) and centrifuge at 1,500×g and 4°C for 15 minutes, discard the material smaller than 50kD, and The product was concentrated to 10ml. After bacteria and impurities were removed again using a 0.22-μm filter, ultracentrifugation was performed at 150,000×g and 4°C for 3 hours using a 90Ti-type rotor, the supernatant was discarded, and the aggregated pellets (pellets) were dissolved in in normal saline (PBS).

[0080] Internal DNA was extracted from lipids by boiling 100 μl of vesicles isolated by the method described above at 100 °C, followed by cooling on ice for 5 min. Then, in order to remove the residual suspension, the DNA was centrifuged at 10,000×g and 4°C for 30 minutes, and o...

Embodiment 3

[0084] Example 3. Metagenomic analysis of bacterial-derived vesicles in the blood of patients with gastric cancer

[0085] After performing metagenomic analysis of blood from 66 gastric cancer patients and 198 age- and sex-matched normal individuals by extracting genes from vesicles present in blood using the method of Example 2, the source of Distribution of vesicles in F. prausnitzii. As a result, it was confirmed that compared with the blood of normal individuals, the vesicles derived from Faecalibacterium prausnitzii were significantly reduced in the blood of patients with gastric cancer (see Table 2 and figure 2 ).

[0086] [Table 2]

[0087]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
absorbanceaaaaaaaaaa
Login to view more

Abstract

The present invention relates to vesicles derived from Faecalibacterium prausnitzii and to uses thereof. It has been experimentally confirmed by the present inventors that the vesicles in the clinicalsamples of patients with gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation,and Parkinson's disease were significantly reduced in comparison with a normal person and that when vesicles separated from the strain were administered, the secretion of inflammatory mediators causedby pathogenic vesicles, such as vesicles derived from colon bacilli, was significantly inhibited. The vesicles derived from Faecalibacterium prausnitzii according to the present invention are expected to be usefully employed for the purposes of developing a method for diagnosing gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer,lymphoma, myocardial infarction, atrial fibrillation, and / or Parkinson's disease, and a composition for preventing, alleviating, or treating said diseases.

Description

technical field [0001] The present invention relates to nanovesicles derived from Faecalibacterium prausnitzii and uses thereof, more specifically, to the diagnosis of gastric cancer, colorectal cancer, liver cancer, and pancreatic cancer by using nanovesicles derived from Faecalibacterium prausnitzii , cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease, and a composition comprising the above-mentioned vesicles for preventing, alleviating, or treating the diseases. Background technique [0002] Since the early 2000s, acute infectious diseases, which in the past were considered epidemics, have become less important, while chronic inflammatory diseases accompanied by immune dysfunction due to discord between humans and microbiomes have transformed disease pattern, becoming a major disease that determines the quality of life and longevity of humans. As intractable chronic inflammatory diseases in th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/689C12Q1/686A23L33/10A61K35/74A61P35/00
CPCY02A50/30A23L33/10A61K35/74A61P35/00C12Q1/689C12Q1/6886C12Q2600/158C12Q1/6883C12Q1/6806C12Q2563/161C12Q2531/113A23V2002/00A23V2250/206A61P9/10A61P9/06A61P25/16A61K9/127
Inventor 金润根
Owner MD HEALTHCARE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap